Dr. Zietman gave a great talk on this paper on 8/23 for the ARRO journal club. For prostate cancer it takes a long time to get a difference in OS, particularly when dealing with low or intermediate risk patients.
Dr. Zietman gave a great talk on this paper on 8/23 for the ARRO journal club. For prostate cancer it takes a long time to get a difference in OS, particularly when dealing with low or intermediate risk patients.
That's nice and all but RTOG 9410 actually looked at locally advanced lung cancer (Stage IIIA/IIIB) which actually doesn't take very long at all to show differences in clinical endpoints, particularly OS.
That's nice and all but RTOG 9410 actually looked at locally advanced lung cancer (Stage IIIA/IIIB) which actually doesn't take very long at all to show differences in clinical endpoints, particularly OS.
The word on the street is that the folks at RTOG wanted to wait until 9408 was published before they could put out 9410. Numbers are there for a reason!
This site uses cookies to help personalize content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies and terms of service.